scholarly journals Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience

2021 ◽  
Vol 10 (02) ◽  
pp. 87-91
Author(s):  
Aparna Sharma ◽  
Atul Sharma ◽  
Vinod Sharma ◽  
Sunil Kumar ◽  
Akash Kumar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Metastatic Disease ◽  
Tertiary Care ◽  
Significant Proportion ◽  
Initial Presentation ◽  
Term Survival ◽  
Metastatic Setting ◽  
Long Term Survivors

Abstract Background Prognosis of metastatic colorectal cancer (mCRC) is poor and goal of treatment is mainly palliative unless there is limited metastatic disease which is surgically resectable. Here, we report a case series of long-term survivors treated predominantly with chemotherapy. Methods This is a single-center retrospective analysis of patients of mCRC. Records of metastatic colorectal cancer patients registered at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, between the year 2005 and 2015 were retrieved and reviewed. Inclusion criteria were patients who survived 5 years or more, treated mainly by chemotherapy, with either initial presentation as metastatic disease or those who progressed after initial surgery with or without adjuvant therapy. The details about the patient characteristics, treatment, and outcome were collected. The data were censored on September 30, 2020. Results Records of 370 mCRC patients were reviewed. Thirty-one patients with all the available details fulfilled the criteria for inclusion in the study. Median age was 53 years (range, 22–74 years). Sixteen were women (51.6%). Twenty-four (77%) were newly diagnosed cases with initial presentation as metastatic disease. Commonest site of primary was on the left (21, 67.6%) followed by right side and transverse colon in 5 patients each. Liver was the most common site of metastasis (n = 18, 58.06%). In metastatic setting, the most common chemotherapy regimen used in the first line was CAPOX (n = 11, 35.48%). Only three patients could undergo metastatectomy. Monoclonal antibodies could be used only in 14 patients. Median overall survival (OS) of this cohort is 81.6 months (95% confidence interval [CI], 69.73–117.9). Conclusion A small but significant proportion of mCRC patients may achieve and maintain durable responses and long term survival with use of combination of chemotherapy with or without biologics.

scholarly journals Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2410
Author(s):  
Chungyeop Lee ◽  
In-Ja Park ◽  
Kyung-Won Kim ◽  
Yongbin Shin ◽  
Seok-Byung Lim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Medical Center ◽  
The Body ◽  
Term Survival ◽  
Postoperative Changes ◽  
Asan Medical ◽  
Colorectal Cancer Patients

The effect of perioperative sarcopenic changes on prognosis remains unclear. We conducted a retrospective cohort study with 2333 non-metastatic colorectal cancer patients treated between January 2009 and December 2012 at the Asan Medical Center. The body composition at diagnosis was measured via abdominopelvic computed tomography (CT) using Asan-J software. Patients underwent CT scans preoperatively, as well as at 6 months–1 year and 2–3 years postoperatively. The primary outcome was the association between perioperative sarcopenic changes and survival. According to sarcopenic criteria, 1155 (49.5%), 890 (38.2%), and 893 (38.3%) patients had sarcopenia preoperatively, 6 months–1 year, and 2–3 years postoperatively, respectively. The 5-year overall survival (OS) (95.8% vs. 92.1%, hazard ratio (HR) = 2.234, p < 0.001) and 5-year recurrence-free survival (RFS) (93.2% vs. 86.2%, HR = 2.251, p < 0.001) rates were significantly lower in patients with preoperative sarcopenia. Both OS and RFS were lower in patients with persistent sarcopenia 2–3 years postoperatively than in those who recovered (OS: 96.2% vs. 90.2%, p = 0.001; RFS: 91.1% vs. 83.9%, p = 0.002). In multivariate analysis, postoperative sarcopenia was confirmed as an independent factor associated with decreased OS and RFS. Pre- and postoperative sarcopenia and changes in the condition during surveillance were associated with oncological outcomes.

Analysis of Prognostic Factors Influencing Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

2007 ◽  
Vol 32 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Marcella Arru ◽  
Luca Aldrighetti ◽  
Renato Castoldi ◽  
Saverio Di Palo ◽  
Elena Orsenigo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Factors Influencing

Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

2008 ◽  
Vol 247 (1) ◽  
pp. 125-135 ◽  
Author(s):  
Myrddin Rees ◽  
Paris P. Tekkis ◽  
Fenella K.S. Welsh ◽  
Thomas OʼRourke ◽  
Timothy G. John
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Erratum to: Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival

2012 ◽  
Vol 20 (S3) ◽  
pp. 751-751
Author(s):  
Sulaiman Nanji ◽  
Sean Cleary ◽  
Paul Ryan ◽  
Maha Guindi ◽  
Subani Selvarajah ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival

Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

2008 ◽  
Vol 247 (6) ◽  
pp. 994-1002 ◽  
Author(s):  
Hiromichi Ito ◽  
Chandrakanth Are ◽  
Mithat Gonen ◽  
Michael DʼAngelica ◽  
Ronald P. DeMatteo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Postoperative Morbidity ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Thirty-Three Long-Term Survivors After Cytoreductive Surgery in Patients With Peritoneal Metastases From Colorectal Cancer: A Retrospective Descriptive Study

2020 ◽  
Author(s):  
Yasuyuki Kamada ◽  
Koya Hida ◽  
Haruaki Ishibashi ◽  
Shouzou Sako ◽  
Akiyoshi Mizumoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Peritoneal Cancer Index ◽  
Complete Cytoreduction ◽  
Clinicopathological Parameters ◽  
Term Survival ◽  
Long Term Survival ◽  
Peritoneal Cancer ◽  
Tertiary Hospitals ◽  
Long Term Survivors

Abstract BackgroundCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with peritoneal metastasis (PM) from colorectal cancer (CRC). However, little has been reported on characteristics and clinical course of long-term survivors with CRC-PM beyond 5 years. The objective of this study was to describe the clinical and oncological features affecting long-term survival of CRC-PM after comprehensive treatment.MethodsBetween January 1990 and April 2015, CRC-PM patients who underwent CRS with or without HIPEC in two Japanese tertiary hospitals and who survived longer than 5 years after the first CRS for PM were retrospectively investigated. Clinicopathological parameters and therapeutic details involved in long-term survival were reviewed. Patients were defined as cured if the recurrence-free interval was > 5 years after the last operation for metastases.ResultsThirty-three patients with a median peritoneal cancer index (PCI) of 4 (range, 1–27) were included. Complete cytoreduction was achieved in all 33 patients, and none had a rectal primary. Recurrence was observed in 19 patients (57.6%) at a median of 2.6 (range, 0.7–7.4) years. Sixteen patients (48.5%) were considered cured, of whom two never developed re-recurrence after the second surgery. The median PCI of cured group was 2 (range, 1–8).ConclusionsLong-term survival and cure were obtained after CRS in selected patients with CRC-PM. Low PCI, complete cytoreduction, and non-rectal primary are associated with long-term survival and cure in PM from CRC.

scholarly journals Characterisation of long-term cancer survivors and application of statistical cure models: a protocol for an observational follow-up study in patients with colorectal cancer

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Sonia Pértega-Díaz ◽  
Vanesa Balboa-Barreiro ◽  
Rocío Seijo-Bestilleiro ◽  
Cristina González-Martín ◽  
Remedios Pardeiro-Pértega ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Follow Up Study ◽  
Cure Models ◽  
Long Term Prognosis ◽  
Clinical Records ◽  
Long Term Survivors

Abstract Background Improved colorectal cancer (CRC) survival rates have been reported over the last years, with more than half of these patients surviving more than 5 years after the initial diagnosis. Better understanding these so-called long-term survivors could be very useful to further improve their prognosis as well as to detect other problems that may cause a significant deterioration in their health-related quality of life (HRQoL). Cure models provide novel statistical tools to better estimate the long-term survival rate for cancer and to identify characteristics that are differentially associated with a short or long-term prognosis. The aim of this study will be to investigate the long-term prognosis of CRC patients, characterise long-term CRC survivors and their HRQoL, and demonstrate the utility of statistical cure models to analyse survival and other associated factors in these patients. Methods This is a single-centre, ambispective, observational follow-up study in a cohort of n = 1945 patients with CRC diagnosed between 2006 and 2013. A HRQoL sub-study will be performed in the survivors of a subset of n = 485 CRC patients for which baseline HRQoL data from the time of their diagnosis is already available. Information obtained from interviews and the clinical records for each patient in the cohort is already available in a computerised database from previous studies. This data includes sociodemographic characteristics, family history of cancer, comorbidities, perceived symptoms, tumour characteristics at diagnosis, type of treatment, and diagnosis and treatment delay intervals. For the follow-up, information regarding local recurrences, development of metastases, new tumours, and mortality will be updated using hospital records. The HRQoL for long-term survivors will be assessed with the EORTC QLQ-C30 and QLQ-CR29 questionnaires. An analysis of global and specific survival (competitive risk models) will be performed. Relative survival will be estimated and mixture cure models will be applied. Finally, HRQoL will be analysed through multivariate regression models. Discussion We expect the results from this study to help us to more accurately determine the long-term survival of CRC, identify the needs and clinical situation of long-term CRC survivors, and could be used to propose new models of care for the follow-up of CRC patients.

Sign in / Sign up

Export Citation Format

Share Document